Holen Sie sich die Stockscreener-App
14.77
0.07%
-0.010
Schlusskurs vom Vortag:
$14.78
Offen:
$14.82
24-Stunden-Volumen:
131.82K
Relative Volume:
0.50
Marktkapitalisierung:
$201.19M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-104.29M
KGV:
-2.4482
EPS:
-6.0329
Netto-Cashflow:
$-81.45M
1W Leistung:
-0.20%
1M Leistung:
+26.13%
6M Leistung:
+122.14%
1J Leistung:
+76.30%
1-Tages-Spanne:
$14.13
$15.00
1-Wochen-Bereich:
$14.13
$15.68
52-Wochen-Spanne:
$5.062
$15.84
Immunic Inc Stock (IMUX) Company Profile
Firmenname
Immunic Inc
Sektor
Branche
Telefon
(332) 255-9818
Adresse
1200 AVENUE OF THE AMERICAS, NEW YORK
Compare IMUX vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
IMUX
Immunic Inc
|
14.77 | 201.19M | 0 | -104.29M | -81.45M | -6.0329 |
VRTX
Vertex Pharmaceuticals Inc
|
485.39 | 123.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
664.52 | 69.67B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.62 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
298.76 | 39.89B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
186.88 | 39.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
Immunic Inc Stock (IMUX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-17 | Eingeleitet | Stifel | Buy |
| 2026-04-15 | Herabstufung | D. Boral Capital | Buy → Hold |
| 2026-03-24 | Eingeleitet | Guggenheim | Buy |
| 2025-11-07 | Eingeleitet | Roth Capital | Buy |
| 2025-09-29 | Eingeleitet | Chardan Capital Markets | Buy |
| 2025-03-25 | Eingeleitet | William Blair | Outperform |
| 2024-11-25 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-09-09 | Fortgesetzt | Leerink Partners | Outperform |
| 2024-08-27 | Eingeleitet | B. Riley Securities | Buy |
| 2022-10-21 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2022-09-19 | Fortgesetzt | H.C. Wainwright | Buy |
| 2021-04-15 | Eingeleitet | Aegis Capital | Buy |
| 2021-03-24 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2020-10-02 | Eingeleitet | SVB Leerink | Outperform |
| 2020-08-26 | Eingeleitet | Piper Sandler | Overweight |
| 2020-08-07 | Fortgesetzt | ROTH Capital | Buy |
| 2020-07-20 | Eingeleitet | BMO Capital Markets | Outperform |
| 2020-06-05 | Eingeleitet | Wedbush | Outperform |
| 2020-05-11 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-03-25 | Eingeleitet | ROTH Capital | Buy |
| 2019-07-11 | Eingeleitet | Chardan Capital Markets | Buy |
Alle ansehen
Immunic Inc Aktie (IMUX) Neueste Nachrichten
Why Did IMUX Stock Surge 33% Pre-Market Today? - Stocktwits
Immunic stock trades steadily as pipeline and Nasdaq listing shape investor focus - ad-hoc-news.de
Immunic announces participation in July investor conferences - Proactive financial news
Immunic to Participate in Investor Conferences in July - PR Newswire
Immunic Names CEO Erik Lundgren to Board - The Globe and Mail
Form 4 Immunic Inc For: 7 July By Investing.com - Investing.com Nigeria
Immunic director granted options for 25,370 shares | IMUX Insider Trading - Stock Titan
IMMUNIC (IMUX) director Barclay Phillips awarded 25,370 stock options as equity pay - Stock Titan
IMMUNIC (IMUX) director receives 25,370 stock options at $14.80 strike price - Stock Titan
Immunic (IMUX) director Jon Congleton granted 25,370 stock options at $14.80 - Stock Titan
Immunic Inc (IMUX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Immunic, Inc. Files Form 8-K Announcing Key Company Details and Executive Update (June 29, 2026) - Minichart
Immunic (IMUX) CEO Erik Lundgren appointed to Board as Tamar Howson retires - Stock Titan
Immunic, Inc. Announces Board and Committee Changes - marketscreener.com
IMUXImmunic Inc Options - Finviz
Form 4 Immunic Inc For: 29 June By Investing.com - Investing.com Australia
Immunic (IMUX) director Jon Congleton awarded 50,740 stock options at $10.90 - Stock Titan
Immunic (IMUX) director receives 25,370 fully vested options - Stock Titan
Immunic (IMUX) director receives grant of 25,370 fully vested options - Stock Titan
Immunic (NASDAQ: IMUX) director receives 25,370 stock options grant - Stock Titan
Immunic (IMUX) director Neermann receives fully vested options on 25,370 shares - Stock Titan
IMMUNIC (IMUX) director Barclay Phillips receives 25,370 fully vested stock options - Stock Titan
IMMUNIC (IMUX) President and COO receives 253,000-share stock option grant - Stock Titan
IMMUNIC (IMUX) CFO awarded stock options for 120,000 common shares - Stock Titan
IMMUNIC (IMUX) director receives 445,000 stock options at $11.60 exercise price - Stock Titan
[Form 4] IMMUNIC, INC. Insider Trading Activity - Stock Titan
Immunic (IMUX) investors boost equity pool and reelect directors at 2026 meeting - Stock Titan
Immunic, Inc.(NasdaqCM: IMUX) added to Russell Microcap Value Benchmark Index - marketscreener.com
Immunic, Inc.(NasdaqCM: IMUX) added to Russell 3000E Value Benchmark - marketscreener.com
Price to earnings forward of Immunic, Inc. – NASDAQ:IMUX - TradingView
Price to earnings forward of Immunic, Inc. – BOATS:IMUX - TradingView
Immunic tests Nurr1 to push beyond MS’s inflammation ceiling - biocentury.com
IMUX Stock Price, Quote & Chart - ChartMill
Enterprise value to revenue forward of Immunic, Inc. – MUN:10V - TradingView
Price to book forward of Immunic, Inc. – MUN:10V - TradingView
IMUX Forecast — Price Target — Prediction for 2027 - TradingView
Enterprise value to EBITDA forward of Immunic, Inc. – NASDAQ:IMUX - TradingView
Immunic (IMUX) Short Interest & Short Float | Updated Jun 2026 - MarketBeat
Price to sales forward of Immunic, Inc. – NASDAQ:IMUX - TradingView
Enterprise value to EBIT forward of Immunic, Inc. – NASDAQ:IMUX - TradingView
Immunic Inc (FRA:10V) Stock Price & 30 Year Financial Data - GuruFocus
Eqs-News: Immunic to Present Additional Phase - Moomoo
Immunic consensus stays bullish, analysts back IMUX shares - AD HOC NEWS
Immunic Inc (IMUX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Immunic Inc (IMUX) Valuation: PE, PB & Fair Value Analysis - TradingKey
Immunic Inc (IMUX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Immunic Inc (IMUX) Institutional Confidence - TradingKey
Immunic Inc (IMUX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Immunic Appoints Distinguished Biopharmaceutical Executive Erik Lundgren as Chief Executive Officer - mcduffieprogress.com
Immunic Inc (IMUX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Immunic Inc (IMUX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Finanzdaten der Immunic Inc-Aktie (IMUX)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.64%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):